Page 4 - Pharmaceutical Companies

Near-term outlook prescription for diagnostic firms looks fragile

Competitive pressures, high valuations limit upsides for listed lab chains

Indoco Remedies gets final nod from US FDA for Lacosamide tablet

Pharmaceuticals firm Indoco Remedies Ltd on Tuesday said it has received final approval from the US health regulator for its generic Lacosamide tablet indicated for prevention and control of seizures. The approval granted by the US Food & Drug Administration (USFDA) for Lacosamide tablets is for strengths of 50 mg, 100 mg, 150 mg and 200 mg. These are the generic version of Vimpat Tablets of UCB Inc, the company said in a regulatory filing. Indoco Remedies Managing Director Aditi Kare Panandikar said, "The ANDA approval for Lacosamide Tablets on the day of patent expiry, reverberates our enduring commitment to make quality and affordable generic medicines available to more patients in the United States. Our first shipment of Lacosamide tablets has already reached the US". Lacosamide tablets are indicated for the prevention and control of seizures. It is an anticonvulsant/antiepileptic drug, the company said. Citing IQVIA sales data for the period ending January 2022, the company ..

Macleods Pharmaceuticals recalls products in US for manufacturing issues

Macleods Pharmaceuticals is recalling two products in the US market due to deviation from standard manufacturing norms, according to a USFDA report.

Pharma industry likely to grow to $130 billion by 2030: Industry leaders

'As India becomes an increasingly more important component for the global supply chain, that should benefit the industry going forward,' Sun Pharma Managing Director Dilip Shanghvi said

Piramal Enterprises Q3 profit rises 11% to Rs 888 crore

The company had posted a net profit of Rs 799 crore for the same period last fiscal year

Pharma company Venus Remedies joins AMR Industry Alliance

AMR Industry Alliance is the largest private-sector coalition working towards curbing AMR through a coordinated and multipronged response

Budget 2022: Pharma industry seeks enhanced funds for healthcare sector

The domestic pharmaceutical industry is expecting an increase in the overall fund allocation for the healthcare sector, focus on policies that encourage R&D activities and continuation of tax concessions on various drugs in the upcoming Union Budget. The industry is also seeking simplification of various processes in order to enhance ease of doing business for the private sector companies. "An increase in the budgetary allocation from the current 1.8 per cent of the GDP to 2.5-3 per cent, as envisaged in the National Health Policy 2017 along with a separate allocation for the bio-pharmaceutical sector R&D is imperative," Organisation of Pharmaceutical Producers of India (OPPI) President S Sridhar told PTI. The industry saw significant momentum over the past year, especially in ensuring access to COVID-19 vaccines and medicines and this year's Budget will be crucial to accelerate sectoral growth and access to innovative health solutions across various diseases and not COVID ...

Australia's Woolworths makes $613 mln drugstore play, taking on Wesfarmers

The 11th-hour move from Woolworths sets the scene for a bid war between Australia's two largest retail companies

HC seeks Centre, Delhi govt's reply on plea for recruiting medicos

The Delhi High Court sought response of the Centre, the Delhi Government, and others on a plea seeking directions to fill the vacancies of doctors and paramedical staff in government-run hospitals

Health ministry panel vetting requests by six cos to make Mucormycosis drug

Development come amid fast spread of disease in various states and shortage of drugs to treat it; Rajasthan has already declared an epidemic

China halting flights to India could hurt pharma supplies, say companies

China supplies 60% to 70% of the raw materials used by India's drugmakers, according to an expert.

India seeks investments from US companies in pharma, medical devices sector

India has reached out to top American pharma companies seeking investment in the country's pharmaceutical and medical devices sector

India's Covid vaccination drive hangs in balance, and so does the world's

When the pandemic ends, it will be with the tremendous assistance of India's pharmaceutical industry.

Vardhman Health to invest Rs 100 crore in adult immunisation outreach

Company earned Rs 500 crore as revenue in FY21 and it plans to double it to over Rs 1,000 crore.

JB Chemicals: New launches, market share gains to drive growth

Key chronic segments have helped the JB Chemicals outperform the Indian pharma market.

Asset monetisation, sales uptick in US key triggers for Glenmark Pharma

The India business is expected to post double digit growth in FY22

Indegene's valuation reaches $700 mn; raises $200 mn from Carlyle, Brighton

Given the wider adoption of digital initiatives within the healthcare industry, Indegene plans to use the funds to accelerate its M&A (merger and acquisition) and global expansion plans

Eris Lifesciences Q3 net up 42% to Rs 90 cr, total income rises by 14%

Overall, the company saw decent growth in its product segments, led by cardio metabolic and vitamin-mineral-nutrients

Reform and incentives

Govt must seek to benefit manufacturing more broadly

As domestic sales decline, drug makers focus on exports to sustain growth

During April-July, drug makers exported products worth $ 7.4 billion, a growth of 9.5 per cent on year on year basis